@article{94b9a5e400d0494da460c193797c98bc,
title = "Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope",
abstract = "The last British Society for Rheumatology (BSR) guideline on PMR was published in 2009. The guideline needs to be updated to provide a summary of the current evidence for pharmacological and non-pharmacological management of adults with PMR. This guideline is aimed at healthcare professionals in the UK who directly care for people with PMR, including general practitioners, rheumatologists, nurses, physiotherapists, occupational therapists, pharmacists, psychologists and other health professionals. It will also be relevant to people living with PMR and organisations that support them in the public and third sector, including charities and informal patient support groups. This guideline will be developed using the methods and processes outlined in the BSR Guidelines Protocol. Here we provide a brief summary of the scope of the guideline update in development.",
author = "Task Toyoda and Zoe Armitstead and Sampada Bhide and Serge Engamba and Emma Henderson and Claire Jones and Pieter MacKeith and Janice Maddock and Gary Reynolds and Nicola Scrafton and Manil Subesinghe and Sujith Subesinghe and Helen Twohig and Mackie, {Sarah L} and Max Yates",
note = "Funding Information: This work was supported by BSR. No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article. S.L.M. is supported by the Leeds Biomedical Research Centre. Funding Information: Disclosure statement: S.L.M. has received consultancy fees on behalf of her institution from Roche/Chugai, Sanofi, AbbVie and AstraZeneca; was an investigator on clinical trials for Sanofi, GlaxoSmithKline and Sparrow; received speaking/lecturing fees on behalf of her institution from Roche/Chugai, Vifor UCB and Pfizer; and was a patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. She received support from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021 virtually. M.Y. reports advisory board work for Galapagos and previous support from Eli Lilly, AbbVie and UCB to attend national and international conferences. All other authors have declared no conflicts of interest. Publisher Copyright: {\textcopyright} 2024 Oxford University Press. All rights reserved.",
year = "2024",
doi = "10.1093/rap/rkae002",
language = "English",
volume = "8",
journal = "Rheumatology Advances in Practice",
issn = "2514-1775",
publisher = "Oxford University Press",
number = "1",
}